General Information of the Drug (ID: M6APDG04036)
Name
CYT-0851
Status
Phase 1/2
TTD Drug ID
DR5VQ1
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
DNA repair protein RAD51 homolog 1 (RAD51)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary DNA repair protein RAD51 homolog 1 (RAD51) is a therapeutic target for CYT-0851. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYT-0851 through regulating the expression of DNA repair protein RAD51 homolog 1 (RAD51). [1], [2]
References
Ref 1 METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis. Elife. 2022 May 3;11:e75231. doi: 10.7554/eLife.75231.
Ref 2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.